Highlight
1. GLP-1 receptor agonists (RAs) are associated with a 17% reduction in overall cancer risk in adults with overweight or obesity.
2. Significant risk reductions occur for endometrial, ovarian, and meningioma cancers.
3. A potential increase in kidney cancer risk has been observed, particularly in younger individuals and those with overweight.
4. Limited but suggestive evidence indicates protective effects against gastrointestinal cancers in type 2 diabetes populations.
